title: Antibody-drug conjugates: Intellectual property considerations.
abstract: Antibody-drug conjugates are highly complex entities that combine an antibody, a linker and a toxin. This complexity makes them demanding both technically and from a regulatory point of view, and difficult to deal with in their patent aspects. This article discusses different issues of patent protection and freedom to operate with regard to this promising new class of drugs.
authors: a Michalski Hüttermann Patent Attorneys ; Düsseldorf , Germany.
authors: Ulrich
authors: U
authors: Storz
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D000617:Aminoglycosides / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D017277:Drug Approval; D000079982:Gemtuzumab; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology* / Q000627:therapeutic use; D018973:Intellectual Property; D008453:Maytansine / Q000031:analogs & derivatives / Q000276:immunology / Q000627:therapeutic use; D010330:Patents as Topic; D000068878:Trastuzumab; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D008453:Maytansine; D000079963:Brentuximab Vedotin; D000079982:Gemtuzumab; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine
keywords: ADC; Kadcyla; antibody; antibody-drug conjugates; freedom to operate; immunotoxin; patent